Login
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV

glpg.com

What Do They Do?

Develops potential medicines for patients with serious diseases and seeks to build its pipeline through business-development deals, with programs in immunology and oncology.

How Do They Make Money?

Partners provide upfront and license fees, milestone payments, and research-cost reimbursements for rights to drug research and related development work; the company also receives royalties as licensed products sell. It earns supply revenue when Jyseleca inventory transfers to Alfasigma.

FY2025 revenue

Who Are Their Customers?

Collaboration partners license its intellectual property and may fund research work; Jyseleca product sales went to wholesalers and hospitals, and the company supplies inventory to Alfasigma.

Do Revenues Turn Into Profits?

Yes. It kept 28.9% of its revenue as net income in FY2025, but spent more cash than it brought in: free cash flow was −EUR 271.2M.

Operating income, FY2025
27% of revenue
▲ Turned profitable vs FY2024 (−EUR 188.3M, −68%)
Net income, FY2025
29% of revenue
▲ +333% vs FY2024 (EUR 74.1M, 27%)
Free cash flow, FY2025
−24% of revenue
▲ +19% (Loss) vs FY2024 (−EUR 336.7M, −122%)

How Are They Changing?

Growing. Revenue grew 4.7x in 4 years, from EUR 234.4M in FY2021 to EUR 1.1B in FY2025, about 48% a year.

Commercial rights transfer Earlier, the company commercialized Jyseleca in Europe itself and through Sobi; the latest report says the Jyseleca business was transferred to Alfasigma, which took over its commercial and development activities.

Pipeline strategy The earlier report described a fully integrated business that discovered, developed, and commercialized medicines; the latest describes a strategy centered on identifying, acquiring, and advancing programs through business-development transactions.

Cell therapy exit The earlier report included CAR-T candidates in its clinical pipeline; the latest report says cell therapy programs are being wound down, leaving a non-cell therapy candidate in the pipeline.

Who Do They Compete With?

Competes with GSK, AstraZeneca, BMS, Abbvie, Idorsia, Viatris, Octapharma, Pfizer, and Argenx

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support